2024-03-05 15:39:10 ET
Gilead Sciences, Inc. (GILD)
TD Cowen 44th Annual Health Care Conference
March 05, 2024 12:50 PM ET
Company Participants
Andy Dickinson - Chief Financial Officer
Conference Call Participants
Tyler Van Buren - TD Cowen
Presentation
Tyler Van Buren
Welcome, and good afternoon, everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, senior biotech analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure to introduce Andy Dickinson, Chief Financial Officer. Andy, thank you very much for being here.
Andy Dickinson
Thank you for us all to be here again. Thanks for having us.
Tyler Van Buren
So, before I get started, if you guys have questions, chime in or raise your hand, and we'll do our best to get them asked.
Question-and-Answer Session
Q - Tyler Van Buren
So to open, Andy, I wanted to start with Gilead's 2024 guidance, and a high-level overview of the business. And perhaps you could elaborate on some of the assumptions behind the 5% year-over-year product sales growth, excluding Biktarvy at the midpoint and how you think this will evolve over the next few years?
Andy Dickinson
Sure, yes, I would be happy to. So maybe just a little bit of background for the audience. Our guidance for the year for our base business and again, we and most of our shareholders look at our base business. We have the world's leading COVID antiviral for hospitalized patients where the sales are still very strong, but they fluctuate as you'd expect from time to time. It's important for patients, it is important for us, but we tend to focus on our base business and base business growth....
Read the full article on Seeking Alpha
For further details see:
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript)